Eisai Q3: Leqembi at-home approvals and oncology wins drive growth
Leqembi at-home subcutaneous approval and launches The FDA approved at-home subcutaneous Leqembi/Iqlik, with launches in the US, plus approvals in China and Japan enabling at-home use. This expands patient access and convenience, potentially boosting sales.
This is a major new approval and launch that directly impacts Eisai's growth prospects.
Strong Leqembi sales and royalty growth Q2 Leqembi sales reached ¥29.3bn, with royalties up 43% excluding China stockpiling. This indicates robust demand and successful commercialization.
Sales and royalty figures are key financial metrics showing Leqembi's market performance.
Oncology pipeline advances UK validated taletrectinib, and the FDA approved WELIREG plus LENVIMA for advanced kidney cancer. These expand Eisai's oncology portfolio and revenue potential.
New approvals and validations in oncology represent additional growth drivers beyond Leqembi.
AI drug-discovery partnership with Nvidia Eisai joined Nvidia’s AI drug-discovery push, which could enhance future pipeline productivity and innovation.
This strategic move may improve long-term R&D efficiency and is a new development.